Evidence map›Paper›PMID 31209791›Full record

ArticleJournal of the American Society for Mass Spectrometry2019

Exploring the Application of the DSA-TOF, a Direct, High-resolution Time-of-Flight Mass Spectrometry Technique for the Screening of Potential Adulterated and Contaminated Herbal Medicines.

Elly Crighton, Jason Weisenseel, Michael Bunce, Ian F Musgrave, Robert Trengove, Garth Maker

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of the American Society for Mass Spectrometry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Molecules (Basel, Switzerland) · 2025
    Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elly CrightonSeparation Science and Metabolomics Laboratory, Murdoch University, South St, Murdoch, WA, 6150, Australia.
Jason WeisenseelPerkinElmer Environmental Health, 710 Bridgeport Ave., Shelton, CT, 06484, USA.
Michael BunceTrace and Environmental DNA (TrEnD) Laboratory, School of Molecular and Life Sciences, Curtin University, Kent St, Bentley, WA, 6102, Australia.
Ian F MusgraveAdelaide Medical School, The University of Adelaide, Adelaide, SA, 5005, Australia.
Robert TrengoveSeparation Science and Metabolomics Laboratory, Murdoch University, South St, Murdoch, WA, 6150, Australia.
Garth MakerSeparation Science and Metabolomics Laboratory, Murdoch University, South St, Murdoch, WA, 6150, Australia. G.Maker@murdoch.edu.au.ORCID http://orcid.org/0000-0003-1666-9377

Funding

Australian Government Research Training Program N/ANational Health and Medical Research Council 1061329
6 · The paper itself

Abstract

Global consumption of complementary and alternative medicines, including herbal medicines, has increased substantially, and recent reports of adulteration demonstrate the need for high throughput and extensive pharmacovigilance to ensure product safety and quality. Three different standard reference materials and five previously analyzed herbal medicines have been used as a proof of concept for the application of adulteration/contamination screening using a Direct Sample Analysis (DSA) ion source with TOF MS on the Perkin Elmer AxION 2 TOF. This technique offers the advantages of minimum sample preparation, rapid analysis, and mass accuracies of 5 ppm. The DSA TOF analysis correlates well with the previous analysis on the initial sample set (which found undeclared herbal ingredients), with the added advantage of detecting previously untargeted compounds, including species-specific flavonoids and alkaloids. The rapid analysis using the DSA-TOF facilitates screening for hundreds of compounds in minutes with minimal sample preparation, generating a comprehensive profile for each sample. Graphical Abstract.

Indexed as

Drug ContaminationCamellia sinensisCapsulesComplementary TherapiesGinkgo bilobaMass SpectrometryPlant PreparationsReference StandardsTabletsTeaVitaminsCapsulesPlant PreparationsTabletsTeaVitaminsAdulterationContaminationDirect mass spectrometryHerbal medicinesPharmacovigilance

Identifiers

PMID31209791

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.